Multivariable analysis for factors associated with ORR, CR rate, PFS, and OS after SOC cilta-cel
| Characteristic . | OR (95% CI) . | P value . |
|---|---|---|
| Best ORR | ||
| Prior BCMA-TT, yes vs no | 0.19 (0.06-0.54) | .002 |
| Ferritin, ≥400 vs <400 ng/mL | 0.20 (0.07-0.51) | .001 |
| Race and ethnicity, Non-White vs White | 6.99 (1.71-49.20) | .02 |
| Sex, male vs female | 0.21 (0.06-0.63) | .01 |
| Best CR or better | ||
| Prior BCMA-TT, yes vs no | 0.20 (0.07-0.54) | .002 |
| Penta-refractory, yes vs no | 0.32 (0.14-0.70) | .005 |
| ECOG PS, 2-4 vs 0-1 | 0.16 (0.05-0.51) | .002 |
| EMD, yes vs no | 0.41 (0.18-0.90) | .03 |
| High-risk cytogenetics, yes vs no | 0.48 (0.22-1.00) | .05 |
| Characteristic . | OR (95% CI) . | P value . |
|---|---|---|
| Best ORR | ||
| Prior BCMA-TT, yes vs no | 0.19 (0.06-0.54) | .002 |
| Ferritin, ≥400 vs <400 ng/mL | 0.20 (0.07-0.51) | .001 |
| Race and ethnicity, Non-White vs White | 6.99 (1.71-49.20) | .02 |
| Sex, male vs female | 0.21 (0.06-0.63) | .01 |
| Best CR or better | ||
| Prior BCMA-TT, yes vs no | 0.20 (0.07-0.54) | .002 |
| Penta-refractory, yes vs no | 0.32 (0.14-0.70) | .005 |
| ECOG PS, 2-4 vs 0-1 | 0.16 (0.05-0.51) | .002 |
| EMD, yes vs no | 0.41 (0.18-0.90) | .03 |
| High-risk cytogenetics, yes vs no | 0.48 (0.22-1.00) | .05 |
| . | HR (95% CI) . | P value . |
|---|---|---|
| PFS | ||
| Prior BCMA-TT, yes vs no | 1.65 (0.94-2.89) | .08 |
| Ferritin, ≥400 vs <400 ng/mL | 2.99 (1.86-4.80) | <.001 |
| High-risk cytogenetics, yes vs no | 1.90 (1.20-3.02) | .006 |
| EMD, yes vs no | 1.96 (1.19-3.23) | .009 |
| OS | ||
| Ferritin, ≥400 vs <400 ng/mL | 3.35 (1.81-6.19) | <.001 |
| High-risk cytogenetics, yes vs no | 2.57 (1.40-4.72) | .005 |
| EMD, yes vs no | 1.88 (1.04-3.42) | .04 |
| . | HR (95% CI) . | P value . |
|---|---|---|
| PFS | ||
| Prior BCMA-TT, yes vs no | 1.65 (0.94-2.89) | .08 |
| Ferritin, ≥400 vs <400 ng/mL | 2.99 (1.86-4.80) | <.001 |
| High-risk cytogenetics, yes vs no | 1.90 (1.20-3.02) | .006 |
| EMD, yes vs no | 1.96 (1.19-3.23) | .009 |
| OS | ||
| Ferritin, ≥400 vs <400 ng/mL | 3.35 (1.81-6.19) | <.001 |
| High-risk cytogenetics, yes vs no | 2.57 (1.40-4.72) | .005 |
| EMD, yes vs no | 1.88 (1.04-3.42) | .04 |
High-risk cytogenetics includes del(17p), t(4;14), and t(14;16). Penta-refractory disease includes refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab or isatuximab.
HR, hazard ratio; OR, odds ratio.